<DOC>
	<DOCNO>NCT02327754</DOCNO>
	<brief_summary>The purpose study investigate effect topiroxostat urinary albumin excretion safety patient early stage diabetic nephropathy hyperuricemia without gout . Participants randomize placebo ( n=20 ) topiroxostat ( n=40 ) 28 week . The investigational drug study supply FUJI YAKUHIN CO. , LTD .</brief_summary>
	<brief_title>Effect Topiroxostat Urinary Albumin Excretion Early Stage Diabetic Nephropathy Hyperuricemia With Without Gout</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<criteria>Diabetes patient Clinically pathologically diagnose diabetic nephropathy Hyperuricemic gout patient Estimated glomerular filtration rate ( eGFR ) &gt; = 30 mL/min/1.73m^2 urine albumin creatinine ratio ( UACR ) great equal 45 less 300 mg/g Patient know nondiabetic nephropathy ( nephrosclerosis )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>